We are pleased to announce that ExogenusTherapeutics has been granted another patent in Japan! This is the second patent granted in this region, and the first one to be granted within the family entitled “Compositions comprising small extracellular vesicles derived from umbilical cord blood mononuclear cells with anti-inflammatory and immunomodulatory properties and process for obtaining them”.
This invention covers the use of exosomes that are naturally secreted by umbilical cord blood mononuclear cells subjected to a specific pre-conditioning, as a therapeutic option for diseases associated to inflammation and immune deregulation. Exogenus Therapeutics has deeply characterized these exosomes and their bioactivity, and demonstrated a multifactorial mechanism-of-action that is largely associated to specific microRNAs.
Our CEO, Joana Correia, and co-inventor of the patent remarked, “This new patent granted in Japan is a milestone for Exogenus Therapeutics, as it allows us to explore a strong international market, strengthens our patent portfolio, and demonstrates our focus in innovation.”
As a leading exosome biotech company, Exogenus Therapeutics is committed to developing innovative, effective, and safe therapies for patients with high unmet medical needs. The company now aims to expand the use of its proprietary exosomes as a treatment for different therapeutic applications that involve regeneration and control of inflammation.
The patent can be accessed here: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020070700&_cid=P11-LXLUZM-96523-1